Today Angle has announced results from a prostate cancer research study carried out by its KOL partner Barts Cancer Institute (BCI). The final data are yet to be published, but headline results indicate that Parsortix can potentially perform as well as or better than current standard of care in terms of detecting early-stage prostate cancer and assessing its severity, and can do so with a simple blood test. While this will require further clinical studies, it represents a likely second clinic
21 Mar 2016
Prostate cancer application gains momentum
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prostate cancer application gains momentum
ANGLE plc (AGL:LON) | 14.8 -0.1 (-4.8%) | Mkt Cap: 38.4m
- Published:
21 Mar 2016 -
Author:
Jonas Peciulis -
Pages:
5
Today Angle has announced results from a prostate cancer research study carried out by its KOL partner Barts Cancer Institute (BCI). The final data are yet to be published, but headline results indicate that Parsortix can potentially perform as well as or better than current standard of care in terms of detecting early-stage prostate cancer and assessing its severity, and can do so with a simple blood test. While this will require further clinical studies, it represents a likely second clinic